Cardiomyopathy
Drug research and approvals for cardiomyopathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 364 studies of cardiomyopathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 33 drug trials for it since 2013, FDA has 9 approved and 16 open orphan designations naming it, and the EU has 4 authorised medicines for it.
- Recruiting worldwide: 364
- Trials authorized in Canada: 33
- FDA orphan approvals: 9
- EU medicines: 4
- A Single-Center, Randomized Controlled Trial of Transcoronary Radiofrequency Ablation Versus Transcoronary Alcohol…NCT07950358 · Not applicable · Ligang Ding · starts Nov 16, 2026
- Multimodal Assessment of Remodeling and Stratification in Heart FailureNCT07940868 · Not reported · Shandong Provincial Hospital · starts Dec 1, 2022
- 31P-MRS Myocardial Energetic Phenotyping and Prognosis Across the Cardiac Disease SpectrumNCT07912086 · Not reported · Chinese Academy of Medical Sciences, Fuwai Hospital · starts Aug 1, 2025
- Differentiating Heart Disease Between Adult-onset Autoimmune and Type 2 DiabetesNCT07911007 · Not applicable · University of Roma La Sapienza · starts Jun 20, 2024
- FAPI PET Imaging in Nonischemic CardiomyopathyNCT07878338 · Phase 2 · Peking Union Medical College Hospital · starts Dec 2, 2025
- Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001NCT07867288 · Phase 1 · Haya Therapeutics, Inc. · starts Oct 30, 2026
- A Phase I Study of Allogeneic Myocardium-Derived Mesenchymal Stem Cells (HB1011) in Patients With Ischemic…NCT07861035 · Phase 1 · HieraBio Inc. · starts Jun 23, 2026
- Patient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial FibrillationNCT07852221 · Not reported · Insel Gruppe AG, University Hospital Bern · starts Jan 5, 2011
- Withdrawal of Heart Failure Treatment Patients With Non-ischemic Cardiomyopathy Who Have Been Super-responders to…NCT07851779 · Phase 4 · Institut d'Investigació Biomèdica de Bellvitge · starts Jan 14, 2026
How its trials ended
1,261 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 200 whose ending is known, 45% met their primary endpoint, 6% missed it and 50% stopped early.
- Ongoing42233%
- Completed, result not reported41333%
- Status unknown22618%
- Met its primary endpoint907%
- Stopped: other or unclear524%
- Stopped: enrollment or feasibility222%
- Stopped: sponsor or business decision131%
- Missed its primary endpoint111%
- Stopped: lack of efficacy5<1%
- Stopped: funding5<1%
- Stopped: safety2<1%
| Apr 1, 2026 | A phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220…ALXN2220 / Wainua, wainzua | AstraZeneca Pharmaceuticals | Ongoing |
| Mar 20, 2026 | A phase 1/2 multicenter, open-label, dose-escalation and dose-expansion trial to assess the safety, tolerability, pharmacodynamics, and preliminary efficacy of…AFTX-201 | Affinia Therapeutics | Ongoing |
| Sep 12, 2025 | Cleopattra: effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy (ATTRCM)Coramitug (NNC6019-0001) | Novo Nordisk | Ongoing |
| Aug 26, 2025 | A phase 3, open-label, multicenter, extension study of acoramidis in patients with newly diagnosed variant transthyretin amyloid cardiomyopathy (actearly ole)Acoramidis (AG10) | Eidos Therapeutics | Ongoing |
| Jun 20, 2025 | A phase 3 global, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of nucresiran in patients with transthyretinmediated…Nucresiran (ALN-TTRSC04) | Alnylam Pharmaceuticals | Ongoing |
| Dec 13, 2024 | Phase 2,adaptive,double-blinded,placebo-controlled,randomized,multi-center trial to evaluate the efficacy,safety and tolerability of intracoronary infusion of…AB-1002 | Asklepios Biopharmaceutical, Inc. | Ongoing |
| Oct 7, 2024 | A phase 2/3 multicenter, randomized, double-blind, placebo-controlled and open-label extension trial to evaluate the efficacy and safety of aficamten in a…Aficamten (CK-3773274) | Cytokinetics | Ongoing |
| Jul 11, 2024 | A follow-up, open-label, research evaluation of sustained treatment with aficamten (CK-3773274) in hypertrophic cardiomyopathy (HCM)Aficamten (CK-3773274) | Cytokinetics | Ongoing |
| May 27, 2024 | Open-label extension study of long-term safety and efficacy of NNC6019-0001 in participants with transthyretin amyloid cardiomyopathy (attr cm)NNC6019-0001 | Novo Nordisk | Ongoing |
| May 22, 2024 | A phase 3, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of aficamten compared to placebo in adults with symptomatic…Aficamten (CK-3773274) | Cytokinetics | Closed |
| Sep 30, 2026 | CamzyosTreatment of adults and pediatric patients weighing 30 kg or more with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve… | MyoKardia, Inc. (a wholly-owned subsidiary of Bristol Myers Squibb) | Approved |
| Dec 19, 2025 | MyqorzoTreatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms | Cytokinetics Inc. | Approved |
| Mar 20, 2025 | AmvuttraTreatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular… | Alnylam Pharmaceuticals, Inc. | Approved |
| Nov 22, 2024 | AttrubyTreatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular… | BridgeBio Pharma, Inc. | Approved |
| Apr 28, 2022 | CamzyosTreatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to… | MyoKardia, Inc. (a wholly-owned subsidiary of Bristol Myers Squibb) | Approved |
| May 3, 2019 | Vyndaqel; VyndamaxVYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis… | FoldRx Pharmaceuticals, Inc., a subsidiary of Pfizer Inc. | Approved |
| Apr 22, 2019 | CorlanorCorlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged… | Amgen, Inc., | Approved |
| Jun 21, 2018 | AblysinolABLYSINOL® is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic… | Belcher Pharmaceuticals, LLC | Approved |
| May 26, 1995 | ZinecardCardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative dose of… | Pharmacia & Upjohn | Approved |
| Jul 21, 2026 | S-Cibenzoline succinateTreatment of obstructive hypertrophic cardiomyopathy (oHCM) | Celltrion, Inc. | Designated |
| Jul 16, 2026 | A non-replication recombinant adeno-associated virus (AAV)…Treatment of dilated cardiomyopathy due to mutations in the BAG3 gene | Affinia Therapeutics | Designated |
| Jun 18, 2026 | NinerafaxstatTreatment of symptomatic nonobstructive hypertrophic cardiomyopathy | Imbria Pharmaceuticals, Inc. | Designated |
| Nov 4, 2024 | IfetrobanTreatment of cardiomyopathy associated with Duchenne muscular dystrophy | Cumberland Pharmaceuticals Inc. | Designated |
| Dec 14, 2023 | Adeno-associated virus serotype rh.10 encoding for the…Treatment of arrhythmogenic cardiomyopathy due to a PKP2 pathogenic variant | LEXEO Therapeutics, Inc. | Designated |
| Sep 21, 2023 | AtibuclimabTreatment of arrhythmogenic cardiomyopathy | Implicit Bioscience Ltd. | Designated |
| Sep 18, 2026 | Tafamidis AccordTafamidis · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Feb 12, 2026 | MyqorzoAficamten | Cytokinetics (Ireland) Limited | EMA ↗ |
| Feb 10, 2025 | BeyonttraAcoramidis | Bayer AG | EMA ↗ |
| Jun 26, 2023 | CamzyosMavacamten | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA